Wall Street brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $9.94 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $4.91 million to $18.92 million. Ultragenyx Pharmaceutical reported sales of $200,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 4,870%. The company is expected to report its next earnings report on Thursday, November 1st.
On average, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $46.08 million for the current financial year, with estimates ranging from $25.22 million to $72.18 million. For the next financial year, analysts anticipate that the business will post sales of $101.60 million, with estimates ranging from $74.10 million to $144.81 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. The company had revenue of $12.79 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same quarter in the previous year, the business posted ($1.72) EPS.
In other Ultragenyx Pharmaceutical news, Director William Aliski sold 3,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $76.66, for a total transaction of $287,475.00. Following the completion of the sale, the director now owns 72,610 shares of the company’s stock, valued at $5,566,282.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total value of $603,469.00. Following the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. Insiders have sold 15,450 shares of company stock valued at $1,283,594 in the last ninety days. Company insiders own 8.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Advisors Asset Management Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $181,000. Hsbc Holdings PLC acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth approximately $213,000. JBF Capital Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $384,000. Strs Ohio lifted its holdings in shares of Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 4,300 shares during the last quarter. Finally, Pier 88 Investment Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $446,000. 96.09% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ RARE traded up $0.56 during trading hours on Wednesday, hitting $74.73. The stock had a trading volume of 518,500 shares, compared to its average volume of 520,149. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -9.99 and a beta of 1.95. Ultragenyx Pharmaceutical has a 52 week low of $41.67 and a 52 week high of $90.98.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.